Results of a clinical test on the oral antidiabetic agent glibornuride (Ro 6-4563)
Leubner, H.
Wiener Medizinische Wochenschrift 123(17): 277-282
1973
ISSN/ISBN: 0043-5341 PMID: 4574026 Document Number: 68938
Document emailed within 1 workday
Related Documents
Schmitt, E.W.; Nijssen, J. 1978: Glibornuride--field study on an oral antidiabetic agent. Results of therapy with gluboride in a large number of patients Die Medizinische Welt 29(29-30): 1170-1174Voss, D.; Fuchs, G.; Schneider, D.; Schneider, J. 1972: Effect of the oral antidiabetic agent glibornuride on blood coagulation, blood platelets, and fibrinolysis Arzneimittel-Forschung 22(Suppl 12a): 2219
Rodríguez-Miñón, J.L.; Herrera Pombo, J.L.; Marrón, J.A. 1971: Clinical experience with RO 6-4563 (Glibornuride) (a new oral hypoglycemic agent) Revista Clinica Espanola 123(5): 439-442
Sieberová, R. 1971: Clinical experiences with administration of oral antidiabetic agent Buformin Casopis Lekaru Ceskych 110(18): 420-421
D'Onofrio, F.; Pempinello, R.; Romis, L. 1972: Clinical and metabolic observations with a new synthetic oral antidiabetic agent, glipizide Arzneimittel-Forschung 22(11): 1879-1881
Behpour, A. 1980: Diabetes in adults and old age. Treatment with an oral antidiabetic agent Zfa. Zeitschrift für Allgemeinmedizin 56(22): 1412-1414
Uglesic, A.; Ljahnicky, N. 1975: Experiences with the oral antidiabetic agent, Glurenorm, in diabetics with kidney diseases Medizinische Monatsschrift 29(9): 408-411
Hesseling, W. 1975: Results of clinical study and Schellong's test with a new retard antihypotensive agent Die Medizinische Welt 26(10): 439-443
Hunold, W. 1975: Results of a controlled clinical study on a new retard antihypotensive agent with reference to Schellong's test Zeitschrift für Allgemeinmedizin 51(8): 383-385
Dhirawani, M.K.; Patel, J.C.; Kabadi, U.M. 1970: A clinical trial with glycodiazine--a new oral antidiabetic compound Indian Journal of Medical Sciences 24(2): 53-62
Maeshiba, Y.; Kiyota, Y.; Yamashita, K.; Yoshimura, Y.; Motohashi, M.; Tanayama, S. 1997: Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys Arzneimittel-Forschung 47(1): 29-35
Grujić, M.; Rizvanbegović, B.; Perinović, M.; Perinović, I.D. 1976: Glurenorm a new peroral antidiabetic agent belonging to the group of sulfonylurea compounds Medicinski Arhiv 30(2): 119-121
Brandt, S. 2013: The clinical effects of zinc as a topical or oral agent on the clinical response and pathophysiologic mechanisms of acne: a systematic review of the literature Journal of Drugs in Dermatology: Jdd 12(5): 542-545
Czerwenka, H.; Maly, J.; Quatember, R.; Tschabitscher, H. 1970: Clinical and test psychological studies with a geriatric agent Wiener Medizinische Wochenschrift 120(13): 217-224
Hepp, K.D. 1983: Fenfluramine as an oral antidiabetic Münchener Medizinische Wochenschrift 125(46): 126-127
Johansen, K. 2001: New oral antidiabetic glitazones Ugeskrift for Laeger 164(1): 76-77
Weber, H. 1971: Clinical experiences with a new spasmoanalgesic agent in double-blind test Zeitschrift für Allgemeinmedizin 47(6): 299-300
Schroner, Z.; Javorsky, M.; Kozarova, M.; Tkac, I. 2011: Pharmacogenetics of oral antidiabetic treatment Bratislavske Lekarske Listy 112(8): 441-446
Schumm-Draeger, P-Maria. 2006: Current treatment with oral antidiabetic agents MMW Fortschritte der Medizin 148(9): 33-35
Haslbeck, M. 1979: New aspects of therapy with oral antidiabetic agents Wiener Medizinische Wochenschrift 199(24): 689-695